focus -WSS

focus

author：comprehensive 2025-09-14 21:58:10 - browse：84276

Golden brain and DNA spiral illustration. -- biotech coverage from STAT — Adobe

The dream of being able to pluck a cell therapy off of a freezer shelf and speedily give it to cancer patients is materializing in the cancer world. Now, a new biotech hopes to do the same for patients with neurological conditions.

Kenai Therapeutics closed a $82 million Series A round Thursday co-led by Cure Ventures, The Column Group, and sovereign wealth fund Alaska Permanent Fund Corp. The San Diego-based biotech has big plans for that money — it’s already identified its lead drug candidate for people with Parkinson’s disease, and plans to move into a clinical trial within the next year.

Kenai — pronounced key-nigh — is developing therapies that use induced pluripotent stem cells, or iPSCs. These highly versatile organisms are derived from skin or blood cells and can be transformed into any type of cell. In Parkinson’s, the idea is that these cells would replace damaged neurons.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： The (many) problems with a new study criticizing cancer screening

leisure time

WSS

Some in Scotland's Orkney Islands want to return to Norway after 550 years

Seth Rogen and Lauren Miller Rogen on Alzheimer's caregiving

Leon Gautier, last member of French D

Leon Gautier, last member of French D

ThunderShirts, dance parties and anxiety meds can help ease dogs' July Fourth dread

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

leisure time

focus

knowledge

Affirmative action in medical school literally saved lives

What drug price negotiations mean for Medicare Part D

Medical leaders decry Supreme Court decision on affirmative action

Crinetics acromegaly drug succeeds in late

Peter Hotez and the public health issue of online harassment

Snackable artificial intelligence, expert AI, and the pharma industry

New air purifier tech could be key to improving indoor air quality

NIH nominee Bertagnolli will get October confirmation hearing

Sports medicine is finally prioritizing gender equality

Ukraine holds disaster drills amid fears Russia could sabotage nuclear power plant

explore

A new House health package & hospitals’ new site

Ethical issues complicate the benefits of medical crowdfunding

The 10 drugs up first for Medicare price negotiation

Ukraine holds disaster drills amid fears Russia could sabotage nuclear power plant

A timeline of the missing Titanic tourist submersible

Kremlin open to talks over potential prisoner swap involving detained US reporter Evan Gershkovich

focus

leisure time

leisure time

hotspot